

Clinical Trial Protocol

Iranian Registry of Clinical Trials

08 Jun 2026

Efficacy of a zinc mouthwash in prevention of head and neck radiotherapy-induced-oral mucositis: A double-blind randomized placebo-controlled trial

Protocol summary

Study aim

Zinc mouthwash in preventing mucositis

Design

Clinical practice includes control group, and two parallel, double blinded and randomized groups.

Settings and conduct

This study is a cohort, blind, randomized controlled trial of 75 patients randomly divided into three groups of 25 controls or interventions. After random selection of patients, they will receive written consent (after explaining its content by the student) and eligible patients will be randomly assigned to one of the interventions by permutation blocks (each group is 25) Group 1: Zinc sulfate mouthwash, Group 2: Placebo mouthwash and Group III oral chlorhexidine. Each patient uses a group of mouthwashes three times a day for 6 weeks. Patients attending the study will be selected from randomly assigned patients to Radiation Clinic of Imam Ali Hospital in Bojnourd. The radiotherapist doctor who is responsible for recording the degree of mucositis and the patient as well as the student responsible for completing the questionnaires, are also unaware of the type of treatment intervention performed in relation to the patient.

Participants/Inclusion and exclusion criteria

Entry requirement: age over 18 undergoing head and neck radiotherapy excluding conditions: co-existing systematic diseases

Intervention groups

Intervention group: 1% zinc sulfate, 1% of wetting factors, surfactants, and various suppositories (methyl cellulose, hydroxypropylmethyl cellulose, xanthan gum) will be used to produce mouthwash. Control group: For the preparation of placebo mouthwash, different factors such as water, ethanol, glycerin, citric acid, methyl paraben and propylene paraben are used. Chlorhexidine mouthwash (Vi-one 0.2% CHX) is prepared as a ready-to-

use preparation. Chlorhexidine mouthwash is used as a positive control.

Main outcome variables

mucositis based on clinical manifestations, severity of mucositis, pain intensity

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20190123042475N1**

Registration date: **2019-06-09, 1398/03/19**

Registration timing: **registered_while_recruiting**

Last update: **2019-06-09, 1398/03/19**

Update count: **0**

Registration date

2019-06-09, 1398/03/19

Registrant information

Name

Marzieh Sahebhasagh

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 58 3224 8568

Email address

m.sahebhasagh@nkums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-04-21, 1398/02/01

Expected recruitment end date

2020-03-20, 1399/01/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Efficacy of a zinc mouthwash in prevention of head and neck radiotherapy-induced-oral mucositis: A double-blind randomized placebo-controlled trial

Public title

Efficacy of a zinc mouthwash in prevention of head and neck radiotherapy-induced-oral mucositis: A double-blind randomized placebo-controlled trial

Purpose

Prevention

Inclusion/Exclusion criteria**Inclusion criteria:**

All the cancer patients over 18 treated by radiotherapy

Exclusion criteria:

Incidence of co-existing systematic diseases

Age

From **18 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **75**

Randomization (investigator's opinion)

Randomized

Randomization description

After random selection, each group will be identified based on the randomized table. In order to receive one of the interventions, they are randomly divided into permutational blocks. The radiotherapist is responsible for recording the degree of mucositis and the participants will not be informed of any grouping. Also, students who are responsible for completing the questionnaires are also unaware of the type of treatment interventions. The physician who is aware of the study and the type of medication will be told the method of selecting and assigning samples based on a randomized table of numbers and each group will be followed up through random selection.

Blinding (investigator's opinion)

Double blinded

Blinding description

This study was a cohort, double-blinded, randomized controlled clinical trial. And will be performed on 75 patients who will be randomly assigned to three 25-patient groups of control or intervention. After completing the preparation of the products, the first

performer places mouthwashes in 120-cc glasses for one week use of the patients and identifies them with codes A, B or C. The radiotherapists who are responsible for recording the degree of mucositis and the patient will not be aware of any groupings done. Also, the student responsible for completing the questionnaire is also unaware of the type of medical interventions. Given the double-blindness of the study, the treatments will be covered in form A, B, C. The doctor who is aware of the study and the type of medication, will be told the method of selecting and assigning samples based on a randomized table of numbers and each group will be followed up through random selection.

Placebo

Used

Assignment

Parallel

Other design features

This will be done for the first time in Iran.

Secondary Ids

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

North Khorasan University of Medical Sciences

Street address

Faculty of Dentistry, Shahriar Blvd, next to Imam Ali Hospital, Bojnurd, Iran

City

Bojnurd

Province

North Khorasan

Postal code

74877-94149

Approval date

2019-03-16, 1397/12/25

Ethics committee reference number

IR.NKUMS.REC.1397.112

Health conditions studied**1****Description of health condition studied**

oral mucositis

ICD-10 code

ICD-70

ICD-10 code description

Oral mucositis (ulcerative)

Primary outcomes**1****Description**

Creating mucositis based on clinical manifestations

(Clinical presentation), severity of mucositis based on the WHO benchmark

Timepoint

In the beginning of the study (before the onset of intervention), 1,2,3,4,5,6,7,8 weeks after commencing oral intake of zinc sulfate

Method of measurement

To test mucositis, the WHO classification system is divided into five degrees Grade 0 : None Grade 1 :Soreness + / - Erythema Grade 2 : Erythema , ulcer , patients can swallow solid diet Grade 3 : Ulcer , Extensive erythema , patients can not swallow solid diet Grade 4 : Mucositis to the extent that alimentation is not possible.

Secondary outcomes

1

Description

Patients' quality of life and complications

Timepoint

at the beginning of the study (before the onset of intervention), 1,2,3,4,5,6,7,8 weeks after commencing oral intake of zinc sulfate

Method of measurement

Quality of life will also be measured using a questionnaire used in previous studies, which measures 0 to 4:Grade 0 (Complications have no effect on daily activities), Grade 1 (Symptoms cause discomfort at least once a week)Grade 2 (symptoms interact with your daily activities more than once a week), Grade 3 (symptoms also interfere with basic activities of life)Grade 4 (symptoms are such that the patient is afraid to leave the home, leading a sharp reduction in the individual's social activities.

Intervention groups

1

Description

Intervention group: 1% zinc sulfate, surfactant, and various suppositories (methyl cellulose, hydroxypropylmethyl cellulose, xanthan gum) will be used to prepare the mouthwash. The first presenter will put the mouthwash in the 120 cc glasses for one week consumption of the patient and they use the mouthwash 3 times a day, 5 cc each time for 6 weeks.

Category

Prevention

2

Description

Control group: All components of the intervention group except zinc will be used to prepare the placebo mouthwash. The first presenter will put the mouthwash in the 120 cc glasses for one week consumption of the patient and they use the mouthwash 3 times a day, 5 cc each time for 6 weeks.

Category

Placebo

3

Description

Control group: Prefabricated Chlorhexidine mouthwash(Vi-one 0/2% CHX) will put in the 120 cc glasses for one week consumption of the patient and they use the mouthwash 3 times a day, 5 cc each time for 6 weeks.

Category

Prevention

Recruitment centers

1

Recruitment center

Name of recruitment center

Emam Ali hospital

Full name of responsible person

Marzieh Sahebnaasagh

Street address

Faculty of Dentistry, Shahriar Blvd, next to Imam Ali Hospital, Bojnurd, Iran

City

Bojnurd

Province

North Khorasan

Postal code

9418654514

Phone

+98 51 3854 8137

Email

M.sahebnaasagh@nkums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Bojnourd University of Medical Sciences

Full name of responsible person

Kaveh Hojjat

Street address

Faculty of Dentistry, Shahriar Blvd, next to Imam Ali Hospital, Bojnurd, Iran

City

Bojnurd

Province

North Khorasan

Postal code

94149-74877

Phone

+98 58 3274 2087

Email

S.Kavehhojjat1@gmail.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Bojnourd University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Bojnourd University of Medical Sciences

Full name of responsible person

Marzieh sahebnaasagh

Position

Specialist Dentistry

Latest degree

Specialist

Other areas of specialty/work

Dentistry

Street address

Faculty of Dentistry, Shahriar Blvd, next to Imam Ali Hospital, Bojnurd, Iran

City

Bojnurd

Province

North Khorasan

Postal code

9418654514

Phone

+98 98583272856

Email

Marzieh.saheb@gmail.com

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Bojnourd University of Medical Sciences

Full name of responsible person

Marzieh Sahebnaasagh

Position

Specialist Dentistry

Latest degree

Specialist

Other areas of specialty/work

Dentistry

Street address

Faculty of Dentistry, Shahriar Blvd, next to Imam Ali Hospital, Bojnurd, Iran

City

Bojnurd

Province

North Khorasan

Postal code

9418654514

Phone

+98 985832728568

Email

Marzieh.saheb@gmail.com

Person responsible for updating data**Contact****Name of organization / entity**

Bojnourd University of Medical Sciences

Full name of responsible person

Marzieh Sahebnaasagh

Position

Specialist Dentistry

Latest degree

Specialist

Other areas of specialty/work

Dentistry

Street address

Faculty of Dentistry, Shahriar Blvd, next to Imam Ali Hospital, Bojnurd, Iran

City

Bojnurd

Province

North Khorasan

Postal code

9418654514

Phone

+98 58 3272 8568

Email

Marzieh.saheb@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available